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Abstract Obscurin and obscurin-associated kinase are two products of the obscurin transcriptional unit that
encodes a recently identified giant muscle-specific protein obscurin. In this study, we characterized the developmental
expression and cellular localization of obscurin and obscurin-associated kinase in cardiac muscle cells. We cloned
murine obscurin-associated kinase and found that it is abundantly expressed in the heart as two isotypes encoded by 2.2
and 4.9 kb sequences. The 2.2 kb isotype of the kinase was more prominently expressed than the 4.9 kb isotype. Both
obscurin and the kinase-like domains were progressively upregulated since the early stages of cardiac development.
Obscurin-associated kinase was expressed at higher levels than obscurin at early stages of cardiomyogenesis. Increasing
intensity of obscurin expression in the developing heart positively correlated with progressive cell differentiation and was
higher in the ventricles compared to the atria. These data were supported by the results of experiments with primary
cardiac cell cultures. Obscurin localization changed from a weakly immunopositive diffuse pattern in poorly
differentiated cells to an intensely immunolabeled cross-striated distribution at the level of mid-A-bands and Z-disks
during the assembly of the myofibrillar contractile apparatus. In dividing myocytes, unlike the interphase cells, obscurin
translocated from disassembling myofibrils into a diffuse granulated pattern segregated separately from a-actinin-
immunopositive aggregates. Obscurin-associated kinase was localized mainly to cell nuclei with increasing
incorporation into the Z-disks during differentiation. Our results suggest that these two novel proteins are involved in
the progression of cardiac myogenesis during the transition to advanced stages of heart development.
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Identification and characterization of a sev-
eral new sarcomeric proteins has significantly
expanded our understanding of the structural
organization and functional regulation of the
contractile system in muscle cells [reviews—
Sanger et al., 2005; Ferrari et al., 2006]. A novel
giant protein named obscurin (820 kDa) has
been recently found in the contractile apparatus
of cardiac and skeletal muscle. Obscurin con-
tains 68 immunoglobulin domains, two fibro-
nectin 3 domains, one calcium/calmodulin
binding domain and a RhoGEF domain, all of
which can potentially be involved in structural
and functional control in muscle cells [Bang
et al., 2001; Young et al., 2001; Russell et al.,
2002]. We have found that the DNA sequence
encoding obscurin is topographically very
closely associated with the sequences encoding
myosin light chain kinase (MLCK)-like motifs,
and that these sequences can be transcribed as a
single transcriptional unit [Russell et al., 2002].
Similar data concerning obscurin isoform gene-
ration by alternative splicing have been reported
recently by Fukuzawa et al. [2005]. Interest-
ingly, MLCK-like protein kinase domains have
been observed in several phylogenetic homologs
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of obscurin in the organisms that belong to
different taxonomic groups including Caeno-
rhabditis elegans and Drosophila melanogaster
[Small et al., 2004; Sutter et al., 2004]. The
structural and functional characterization of
the protein products encoded by these domains
in different species is important for better
understanding of the physiological role of
obscurin in striated muscle cells.
The MLCK family plays an essential role in
regulation of actin/myosin organization, sarco-
mere assembly and cytoskeletal dynamics [Aoki
et al., 2000; Kamm and Stull, 2001]. Several
large muscle-specific proteins such as titin,
projectin, twitchin, and stretchin contain pro-
tein kinase domains more or less structurally
similar to MLCK [for discussion see Sutter
et al., 2004]. In addition to their serine/threo-
nine kinase motifs, these proteins contain
multiple immunoglobulin (Ig) and fibronectin
(Fn) domains that mediate interactions with
myosin and other sarcomeric and cytoskeletal
components. All these proteins possess both
structural and signaling functions. For ins-
tance, titin, the largest known member of the
family, acts as a molecular ruler, organizing the
sarcomeric structure through interprotein inter-
actions. It was found that its kinase domain,
known to be required for sarcomere assembly
[Mayans et al., 1998], carries some resemblance
to MLCK [Seberstyen et al., 1996] and is
involved in the control of muscle gene expres-
sion and protein turnover [Lange et al., 2005].
Obscurin-associated kinase is the product of
the same transcriptional unit that encodes
obscurin, and its expression depends on alter-
native translation initiation sites. In the mam-
malian heart, the ‘‘large’’ obscurin isoform does
not routinely contain the kinase domain, and
the kinase-containing sequences can be express-
ed as a separate entity [Russell et al., 2002].
Therefore, obscurin and obscurin-associated
kinase are separate transcripts from a ‘‘split’’
gene, not unlike the giant Drosophila MLCK,
stretchin [Champagne et al., 2000]. Earlier
we reported that kinase-containing isotypes of
obscurin can be expressed autonomously in the
overloaded mammalian heart in vivo [Borisov
et al., 2003].
The expression of these genes during muscle
development and cellular localization of their
products has not been comparatively charac-
terized. Assembly of myofibrils and cytoskeletal
remodeling are integral components of myocar-
dial differentiation and adaptive responses. For
this reason, understanding of the developmen-
tal patterns allows us to collect more informa-
tion concerning the functional role of these
proteins. In this study, we examined the devel-
opmental expression and cellular localization of
obscurin and obscurin-associated kinase.
MATERIALS AND METHODS
Cloning of the Murine Obscurin-Associated
Kinase Isoforms
cDNA sequence from the human obscurin-
MLCK were compared to the high throughput
genome sequence database at the National
Center for Biotechnology Information using
the BLASTN [Altschul et al., 1990] sequence
homology search. The search identified signifi-
cant homology between the cDNA sequence and
sequence from three human chromosome 1q42
BAC clones two mouse chromosome 11 BAC
clones (RP23-344L20 and RP23-441I8). The
aligned mouse sequence was assembled to
create a draft murine obscurin-MLCK cDNA
sequence. Three overlapping sets of PCR pri-
mers were selected using the Primer Select
subroutine of the Lasergene sequence analysis
program (50F: gggcgccggtaccacaggtcactattg, 50R:
ggcgccactagcttcccctcgtag; midF: tggcccggcacc-
tacgag, midR: ggtaccaggcctgccttctttctg; 30F:
gggatccaaccgcacggtggggaaggttacg, 30R: gtggg-
caggaagcgcaagtggtc). The primers were used to
amplify the corresponding cDNA sequences
from a mouse heart cDNA library (Clontech,
Inc.). The PCR products were subcloned and
completely sequenced on both strands. This
sequence was assembled to create the final
murine obscurin-MLCK isoform cDNA sequen-
ce. Sequence from the 30 end of the murine
obscurin sequence was identified by BLASTN
sequence homology search and used to generate
riboprobes for RNA in situ hybridization.
Northern Blot Analysis
Probes were generated from the 50 and 30
serine-threonine kinase encoding regions of
obscurin MLCK and the 30UT region of obscurin
using random-prime labeling as directed by
the manufacturer (Life Technologies, Inc.).
Hundred nanograms of each probe was labeled
with 5 mCi aP32-dCTP using previously describ-
ed methods [Russell et al., 2002]. Between
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hybridizations, the blots were stripped by brief
immersion in 1% SDS/0.01% SSC at 1008C.
Reverse Transcription-Quantitative Polymerase
Chain Reaction Analysis
Embryos were isolated at 10, 12, 12.5, 14, and
17 dpc and hearts were extracted. Total RNA
was isolated from whole heart (10 and 12.5 dpc),
left ventricle (12, 14, and 17 dpc), and right
ventricle (12, 14, and 17 dpc) using the TRIZOL
reagent (Invitrogen). Poly A RNA was prepared
from total RNA using Poly A Tract kit (Prom-
ega). Primers were designed to amplify terminal
kinase, internal kinase, and Rho domains [Heid
et al., 1996]. The conditions for RT-PCR were as
follows: 30 min at 608C (reverse transcription),
10 min at 958C (reverse transcriptase inactiva-
tion and AmpliTaq Gold activation), and then
15 s at 958C, 1 min at 608C, for 40 cycles (PCR
amplification).
Whole Mount In Situ RNA Hybridization
After plasmid linearization with SacI and
SacII, respectively, digoxigenin-UTP labeled
sense and antisense riboprobes were tran-
scribed from inserts encoding for part of the
terminal serine-threonine kinase of obscurin-
MLCK (545 bp) and the 30 untranslated region of
obscurin (497 bp; Fig. 1). Hearts were extracted
from 12.0, 14.0, and 17.0 dpc mouse embryos.
The embryos were fixed overnight at 48C with
4% paraformaldehyde in phosphate-buffered
saline (PBS, pH 7.4). In our experiments we
used Dulbecco’s modification of phosphate buf-
fered saline (KCl 200 mg/L, KH2PO4 200 mg/L,
NaCl 8,000 mg/l, and Na2HPO4 1,150 mg/l). The
embryos and hearts were then dehydrated in a
graded series of 25, 50, 75, and 100% methanol
in PBT (PBS with 0.1% Triton X-100) and stor-
ed at 208C. Following rehydration in graded
methanol, embryos, and hearts were processed
Fig. 1. A: Schematic representation of the obscurin-associated
MLCK-like single and dual kinase isoforms. Putative functional
domains identified by PROSITE search include two serine
threonine kinase (SKI and SKII), two immunoglobulin-like (Ig),
and one fibronectin-like (Fn) domains. Antisense RNA and cDNA
probes, for in situ and Northern analysis respectively, were
prepared using cDNA sequence from the underlined regions.
A polyclonal antibody generated to human obscurin-associated
MLCK-like kinase recognizes the epitopes in the SKI domain
(indicated by the pink square and short line on the right).
B: Northern blot analysis of obscurin-MLCK mRNA expression
in adult murine tissues. The single kinase isoform, detected with
the SKI probe, is selectively expressed in the heart (H) and not
detectable in other tissues including brain (Br), spleen (S), lung
(Lu), liver (Li), skeletal muscle (SM), kidney (K), and testis (T). The
dual kinase isoform (the pink square and the short line on the left
in the panel A), detected with the SKII probe, was expressed in
the heart and skeletal muscle (SM). Larger transcripts may reflect
rare inclusion of the kinase domains at the end of the obscurin
transcript. C: Western blot analysis using the anti-obscurin-
MLCK-like terminal kinase antibody. The antibody detected the
native obscurin-MLCK single kinase isoform in lysates from
adult rat cardiac myocytes in culture and in lysates of Cos7
cells transfected with an obscurin-MLCK expression construct
(a positive control, marked withþ) but not with a control plasmid
(a negative control, marked with ). [Color figure can be viewed
in the online issue, which is available at www.interscience.
wiley.com.]
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as described by [Wilkinson, 1992]. The hearts
incubated without the specific probe served as a
negative control. Omission of the specific probe
served as negative control for this technique.
After in situ hybridization, specimens were
post-fixed in 4% paraformaldehyde in PBS,
and digital microscopic images were taken soon
after completion of the reaction.
Antibody Preparation and Characterization
A 580 bp cDNA encoding for most of the
terminal kinase domain of obscurin-MLCK
(Fig. 1) was cloned into the pRSET expression
vector and the protein expressed in the E. coli
strain BL21(DE3)pLysS. Induction of expres-
sion was carried out at 378C using 0.1 M
isopropyl-B-D-thiogalactopyranoside (IPTG).
Cells were harvested 5 h after induction of
expression, and expressed protein was purified
and dialysed according to Invitrogen’s Xpress
system protein purification protocol. The pro-
tein was isolated under denaturing conditions
and purified using Invitrogen’s ProBond resin.
The eluted protein was dialyzed against 10 mM
Tris, pH 8.0, 0.1% Triton X-100 overnight at
48C to remove urea. The purified protein was
supplied to Bethyl laboratories (Montgomery,
TX) for production of polyclonal rabbit antisera.
Antibody purification was performed with pro-
tein A column (Pierce Inc., Rockford, IL) follow-
ing the manufacturer’s instructions. Western
analysis was performed, using standard proce-
dures, on cell lysates of NIH3T3 cells 48 h after
transfection with a plasmid construct express-
ing the full length single kinase isoform. The
work on the antibody development and testing
of its specificity was performed by Dr. M. Raeker
with the technical assistance of a specialized
core at the University of Michigan Medical
School.
Primary Cardiac Muscle Cell Cultures
Primary cell cultures of neonatal cardiac
myocytes have been isolated from the hearts of
2- to 3-day-old rats by enzymatic dissociation of
myocardial tissue with trypsin and collagenase
as previously described [Borisov et al., 1985,
1989]. Isolated cells were plated on glass cover-
slips in 60 mm Petri dishes. The cells were
cultivated in a CO2 incubator (5% CO2) in F-12
medium containing 10% of bovine fetal serum
and were collected for immunolabeling every
24 h after plating.
Immunocytochemistry and
Confocal Microscopy
Cell fixation, processing, and immunolabel-
ing were performed as previously described
[Borisov et al., 1989, 2001]. The samples of
mouse fetal cardiac tissue were prepared,
sagittally cryosectioned, mounted on histolog-
ical slides and processed according to the
protocols that we described earlier [Borisov
et al., 2001]. Similar techniques were applied
to a set of rat cardiac tissue samples. The
development and characterization of the mono-
clonal antibody to the sarcomeric isoform of
a-actinin and its use for studies of myogenic
differentiation were previously described [Bor-
isov et al., 1989; Fridlianskaia et al., 1989]. This
antibody, clone EA53, is now marketed by
Sigma Chemical Co., St. Louis, MO. A poly-
clonal antibody recognizing the carboxy-termi-
nal region of obscurin was prepared in a rabbit
host using standard methods, and its specificity
has been examined [Kontrogianni-Konstanto-
poulos et al., 2003]. This antibody was kindly
provided to us by Dr. K. Kontrogianni-Konstan-
topoulos and Dr. R.J. Bloch, Department of
Physiology, the University of Maryland. We
used two negative controls in our immunocyto-
chemical reactions: (1) omission of the primary
antibody to myofibrillar proteins, and (2) the
labeling of extracardiac connective tissue
known to be immunonegative for both obscurin
and a-actinin. Both negative controls demon-
strated the specificity of the immunolabeling
reactions. Non-specific binding was blocked
with 1% bovine serum albumin in PBS. In
double-labeling indirect immunofluorescence
experiments, we incubated the samples with
the monoclonal antibody to a-actinin diluted
1:400 for 2 h, washed the cells three times for
3 min in PBS, then incubated the samples with
the polyclonal antibody to obscurin diluted 1:45
for 2 h and washed three times for 3 min in PBS
at room temperature. The solution of the seco-
ndary anti-mouse and anti-rabbit antibodies
conjugated with FITC and rhodamine, respec-
tively, was used to label the cells for 45 min.
The secondary antibodies were purchased from
Sigma Chemical Co. Immunolabeled samples
of cultured cardiac muscle cells were washed
three times for 3 min with PBS at room tem-
perature, mounted on histological glass slides
using the embedding medium for immunofluor-
escence (Sigma Chemical Co.) and examined in
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a Zeiss LSM 510 Meta confocal microscope using
the objectives 40 and 63.
RESULTS AND DISCUSSION
Cloning of the Murine Obscurin-Associated
Kinase Isoforms
The amino acid sequences of the human and
mouse obscurin-associated kinase isoforms
were compared using BLAST sequence similar-
ity search (blastp, pairwise blast format). The
assembled mouse and human cDNA sequences
would be predicted to encode for 1,585 amino
acid and 1,610 amino acid proteins, respec-
tively. Analysis of the predicted proteins, using
a PROSITE database search, determined that
both the mouse and human obscurin-associated
kinase isoforms would have two immunoglobu-
lin domains and two putative serine-threonine
kinase domains (Fig. 1). PROSITE search also
identified a domain with fibronectin homology
between the terminal immunoglobulin and
serine-threonine kinase domains that had not
been recognized in the human cDNA sequence.
This putative fibronectin domain is conserved in
the human with 82% amino acid identity and
87% conserved amino acids between the mouse
and human amino acid sequence within this
77 amino acid domain.
Both the mouse and human obscurin-
associated kinase-like transcripts also share a
conserved putative translation initiation site
(mouse: ggggccccgtccATGcaggtc; human: gggc-
ccccatccATGcaggta) and predicted amino ter-
minal nine amino acids (MQVTIEDVQ). The
search revealed 76% sequence identity between
the two predicted proteins with much higher
degrees of similarity between the corresponding
serine-threonine kinase domains (SK1: 89%
identity; SK2: 88% identity; Fig. 1). The most
striking divergence between the sequences
occurred between the amino terminal serine-
threonine kinase domain and the carboxy
terminal immunoglobulin domain (65% iden-
tity). This amino acid sequence does not have
any identified functional domains and has no
significant homology to other known proteins.
The bulk of this region is encoded for by a single
large exon, 1,988 bp in the mouse and 2,063 bp
in the human as we demonstrated earlier
[Russell et al., 2002]. The putative translation
initiation site for the single kinase-containing
transcript does not appear to be conserved
between the human and the mouse. In both
species, a good Kozak consensus start sequence
is present at the 30 end of the large exon,
however, the start in the mouse occurs approx-




The expression pattern of the murine
obscurin-associated kinase isoform was inves-
tigated using Northern blotting analysis. As
in the human, the obscurin-associated kinase
isoforms are predominantly expressed in the
heart. In contrast to the human gene, the 2.2 kb,
single obscurin-associated kinase-encoding iso-
form is much more prominently expressed than
the 4.9 kb, SK-II-encoding isoform (Fig. 1). The
probe corresponding to the carboxy terminal
serine-threonine kinase region detected tran-
scripts of 4.9 kb and several larger transcripts
as well in both the heart and skeletal muscle.
The larger transcripts may represent obscurin
isoforms that include this kinase domain, which
is supported by Northern analysis with a probe
for the murine obscurin RhoGEF encoding region
(unpublished results). Although not detectable
by Northern analysis, the proteins similar to
obscurin-associated kinase do appear to be ex-
pressed at low levels in multiple tissues. BLAST
sequence homology search revealed murine ESTs
from adult inner ear, diaphragm, and neo-natal
lung that represented the sequences similar to
obscurin-associated kinase transcripts.
The structure of these genes appears to
be conserved among mammalian species, and
the translation initiation sites for the two genes
are approximately 140–170 kb apart in the
mouse, rat and human genomes. The tran-
scription initiation site for obscurin-associated
kinase isoforms has not been definitively iden-
tified as yet, and there is no evidence to suggest
that it shares the same initiation site as the
large obscurin transcript. Northern analysis
with probes from the 50-untranslated region of
obscurin do not detect the obscurin-associated
kinase transcript and RT-PCR, using primers
from the obscurin 50-untranslated sequence,
have not been able to amplify products
when paired with primers from the obscurin-
associated kinase region (unpublished results).
The level of expression does suggest that
at least some regulatory elements differ be-
tween the two sets of transcripts. By Northern
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analysis, the obscurin-associated kinase 2.2 kb
transcript appears to be much more highly
expressed than the much larger obscurin tran-
script in adult mouse tissues. Since Northern
analysis can be affected by probe affinity and
by low efficiency preparation, separation and
transfer of high molecular weight RNAs, the
relative amount of expression of obscurin and
the kinase was compared using RT-qPCR. The
efficiency of amplification for the obscurin and
the kinase-encoding products were similar
based on serial dilutions of starting RNA. The
obscurin-associated kinase single kinase iso-
form was expressed about 50-fold greater than
the obscurin transcript. Again, differences in
the efficiency of mRNA isolation between the 25 kb
obscurin and the 2.2 kb obscurin-associated
kinase transcripts may account for some of the
difference. The fold difference is consistent
with the findings of Nagase et al. [2000] who
isolated fragments of both obscurin and
obscurin-associated kinase, which they named
KIAA1556 and KIAA1639, respectively. Using
reverse-transcription-coupled polymerase chain
reaction, the products of which were quantified
by enzyme-linked immunosorbent assay, these
authors demonstrated that KIAA1556 and
KIAA1639 had a similar pattern of distribution
in human adult tissues but that, in general,
KIAA1639 was expressed approximately 50-fold
greater.
The difference in the obscurin-associated
kinase isoform expression patterns between
the mouse and the human may reflect the
differences in the myocardial physiology be-
tween the two species. One of the most striking
differences between the murine and human
heart contractile activity is their resting heart
rates. Murine heart rates range from 300 to
400 beats per minute compared to a normal
human heart rate of less than 90 beats per
minute. This more rapid heart rate shortens
the ventricular filling time, necessitating rapid
myocardial relaxation. Other important differ-
ences include their inotropic and chronotropic
responses to adrenergic stimulation. Thus, it
remains to be determined whether differences
in the kinase isoform expression facilitate some
of these physiologic differences.
Developmental Expression of Obscurin and
Obscurin-Associated Kinase in Cardiac Tissue
Using RNA in situ hybridization, we found
that the expression of obscurin and obscurin-
associated kinase transcripts in mouse car-
diac tissue was not visually detectable until
embryonic day 10, but by day 12 post-conception
there was significant expression in both the
left and right ventricle (Fig. 2A–D). We used
murine hearts in these experiments because our
probes were mouse-specific. As noted in the
whole mount in situ hybridization analysis of
the hearts isolated from 12-day embryos, there
was intense reactivity for obscurin-associated
kinase in the ventricles and relatively little
expression at this point in the developing atria
(Fig. 2A,B). Similar differences in compart-
ment-specific expression between the atria and
the ventricles have been observed for obscurin
(Fig. 2C,D). The intensity of labeling of the
ventricular tissue for obscurin-associated kin-
ase was higher than the intensity of labeling for
obscurin (compare Fig. 2A,C). The comparison
of these two labeling patterns suggests that the
intense expression of obscurin during develop-
ment is activated later than the expression of
obscurin-associated kinase.
Fig. 2. Expression of obscurin and obscurin-associated kinase
during mouse cardiac development. Whole mount RNA in situ
hybridization of obscurin (A) and obscurin-associated kinase (C).
Note weak to moderate level of obscurin expression in the
ventricles (A) and the prominent ventricular expression of
obscurin-associated kinase (C) 12 days post-conception. Also,
note that the atria visible on the upper part of the photos show a
considerably lower level of reactivity than the ventricles. A,B
show the lateral views of the heart, and C,D show the frontal
views of the heart. The letter a marks the atria. B,D show a
negative control incubated without the specific probe demon-
strating the specificity of the in situ hybridization reaction, 21.
[Color figure can be viewed in the online issue, which is available
at www.interscience.wiley.com.]
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This localization study supported the results
of our Northern blotting experiments that
demonstrated low levels of obscurin expression
at early stages of cardiomyogenesis. A lower
level of obscurin expression in the atrial tissue
compared to the ventricles can be explained by
the fact that the differentiation of the contrac-
tile system in the developing atria occurs at
later stages of embryonic development and
proceeds less intensely compared to the ven-
tricular myocytes [for literature see Borisov and
Rumyantsev, 1991; Rumyantsev, 1991]. Very
low levels of expression of obscurin-associated
kinase encoding transcripts were also detect-
able in the developing central nervous system
(unpublished data).
The developmental pattern of obscurin ex-
pression and localization was further studied
using indirect immunofluorescent protein label-
ing of fetal mouse and rat embryonic tissue
sections and in primary cultures of rat cardiac
muscle cells. Both obscurin and obscurin-asso-
ciated kinase were noted to be expressed in the
developing heart at the protein level. We found
that obscurin expression progressively increas-
ed during myocardial development directly
correlating with the increasing level of cardiac
muscle differentiation. The results of immuno-
labeling of the mouse cardiac tissue at different
stages of embryonic development are presented
in Figure 3A–F. Interestingly, at early stages of
cardiac wall morphogenesis the immunolabel-
ing for obscurin in the heart had a tendency to be
more intense in the subendocardial developing
trabecular areas compared to the forming
middle compact layer and the subepicardial
layer of the ventricular wall (Fig. 3A). This
difference appears to reflect the gradients of cell
differentiation in the developing heart with less
advanced cell differentiation and increased cell
proliferation in the compact layer of the devel-
oping ventricles. Several studies demonstrated
that as myocytes move away from the compact
zone toward the trabecular zone, they become
progressively differentiated and their rate of
proliferation declines [for literature see Thomp-
son et al., 1990; Tokuyasu, 1990; Rumyantsev,
1991]. In these areas, the cells proliferating at a
slower rate have more developed contractile
structures. This suggests that the accumulation
of obscurin in the subendocardial myocyte
populations at this stage is explained by the
development of a more mature myofibrillar
apparatus. As development proceeded, the
intensity of immunolabeling reflecting the level
of obscurin expression in the growing heart
considerably increased (Fig. 3B–D,F). By day
13 post-conception the presence of obscurin was
detected in all myocytes in the developing heart
wall, and the transmural gradient observed at
earlier developmental stage was not clearly
expressed (Fig. 3B). The labeling was specific to
muscle cells, and was not found in the non-
muscle tissues adjacent to the growing heart
(Fig. 3B). An additional negative control that
included the omission of the primary antibody
(Fig. 3D) also demonstrated the specificity of the
immunocytochemical reaction. The intensity of
tissue labeling increased, and the development
of elements of structured fibrillar pattern
rapidly progressed during development (com-
pare Fig. 3A,B). Figure 3E taken at a higher
magnification clearly shows that at this stage
obscurin was detected both as diffuse labeling
and as the cross-striated periodic pattern
typical of differentiating myofibrils. This proc-
ess coincided with the progressive trabeculation
in the ventricles. By the time of trabecular
fusions and the advanced development of the
interventricular septum, the intensity of label-
ing of myocardial tissue further increased, and
obscurin localization acquired more organiz-
ed granulated, dotted and fibrillar structural
patterns (Fig. 3C). After completion of the
trabecular fusion and formation of compact
ventricular walls, obscurin expression remain-
ed upregulated compared to earlier stages, and
the structural association of obscurin with the
contractile apparatus became the predominant
type of localization of this protein (Fig. 3F). The
developmental dynamics of obscurin localiza-
tion in the rat heart was very similar to the
structural patterns described above in the
mouse heart (unpublished results).
Obscurin-associated kinase demonstrated a
different pattern of intracellular localization.
Intense immunopositivity for this protein in
vivo was found in mouse and rat cardiac muscle
cell nuclei with some moderate presence in the
cytoplasm (the insert in Fig. 7B). It was difficult
to determine its precise intracellular protein
localization in tissue sections because of the
heterogeneity of cell populations in vivo, invis-
ibility of clear cell boundaries, very close super-
imposition of individual cells and neighboring
sectioned cell fragments. When we immunola-
beled the tissue for sarcomeric proteins as the
second label to differentially visualize muscle
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cells, the fluorescent signal was too intense to
identify the details of nuclear and cytoplasmic
structure and to determine the intercellular
protein localization in individual myocytes. For
this reasons, we performed a high resolution
microscopic analysis of obscurin and obscurin-
associated kinase localization in relation to the
contractile apparatus in isolated intact heart
cells in culture (see Figs. 7A–D and 8A–D and
the text in the next section below).
Thus, we found that the tissue specific
expression of obscurin and its kinase isotype
was upregulated during myogenesis and that
the expression of obscurin-associated kinase
Fig. 3. Expression of obscurin in the developing myocardium.
Immunofluorescent labeling for this protein in the developing
free left ventricular wall on days 11, 13, 14.5, and 16-day post-
conception is illustrated in A–C,F, respectively. Note the
increasing levels of obscurin expression during cardiac develop-
ment and its shift from the diffused pattern to more intensely
labeled structured dotted and periodic fibrillar distribution in
the tissue. D: Negative control: the section of the heart on day 13
post-conception incubated only with the secondary antibody
(compare to panel B). V marks the ventricular cavity. Asterisks in
B indicate the non-muscle tissue immunonegative for obscurin
and located close to epicardial surface of the ventricular wall.
The arrow in B indicates the area shown in panel E at a high
magnification. C: The ventricular wall following trabecular
fusion located closely to the apical area of the heart near the
interventricular septum. Arrowheads in D show the boundaries
of the immunonegative cardiac tissue in a negative control
sample. E: The area marked with the large arrow in panel B
presented at a higher magnification as a single confocal optical
section. The arrows in B and E show the same group of cells. At
this stage of obscurin is visualized both as the diffuse labeling
pattern and as the developing elements of the striated myofibril-
lar pattern. Small arrows in E show the elements of sarcomeric
cross-striation. A–D, F: 280; E: 630.
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could be detected at higher level prior to the
intense expression of obscurin. This apparent
earlier expression of the kinase-like sequence at
the transcriptional level appears to allow this
protein to attain a higher level of expression
in the developing heart sooner than that of
obscurin. This interpretation is also support-
ed by our data of reverse transcriptase primed
quantitative PCR analysis of obscurin and
obscurin-associated kinase mRNA expression
under conditions of cardiac hypertrophy in vivo
suggesting that the kinase-containing isotype
can be upregulated earlier and to a greater
extent than obscurin [Borisov et al., 2003].
Differential Cellular Localization of Obscurin
and Obscurin-Associated Kinase
To determine the intracellular localization of
obscurin and obscurin-associated MLCK-like
kinase more precisely, we studied their topo-
graphical distribution in rat cardiac myocytes in
culture. It was much more difficult to isolate
large numbers of functionally active mouse
cardiac muscle cells and to maintain them in
culture. For this reason in the present study
we used a rat cell model. These experiments
allowed us to examine the localization of these
proteins in the whole volume of intact, individ-
ual myocytes, which was impossible to achieve
using tissue sections. Indirect immunolabeling
for sarcomeric a-actinin that localizes to the
Z-band in mature myofibrils was used to
selectively identify myocytes in primary cell
cultures and to evaluate the degree of their
myofibrillar differentiation [for literature see
Borisov, 1991]. Our results showed that in car-
diac myocytes obscurin and obscurin-associated
kinase were localized differentially at the
cellular level. Using double indirect immuno-
fluorescent labeling of cell cultures for sarco-
meric a-actinin and obscurin, we found that the
localization of obscurin was entirely cytoplas-
mic and muscle-specific and that it was asso-
ciated with progressive maturation of the
sarcomeric contractile apparatus (Fig. 4A–C).
Obscurin was found in mature sarcomeres and
was the most abundant in the middle of A-bands
at the level of the M-lines, particularly in the
myofibrillar clusters. As one can see from
Figure 4A–D, double immunolabeling of the
sarcomeric isoform of a-actinin and obscurin in
the same cells clearly demonstrated that the
incorporation of obscurin temporally coincided
with the accumulation of laterally aligned
mature myofibrils (Fig. 4D). Unlike the inter-
phase cells, during mitotic division obscurin
was found in granulated aggregates scattered
in the cytoplasm and spatially separated from
the granulated aggregates containing a-actinin
(Fig. 5). This shows that during mitosis obscurin
may form either homophilic protein aggregates
or may establish structural complexes with the
sarcomeric proteins distinct from a-actinin.
Thus, the localization pattern of obscurin is cell
cycle-dependent.
The specificity of the antibody to obscurin
used in this experiments has been described
earlier [Kontrogianni-Konstantopoulos et al.,
2003], and the specificity of the antibody to
obscurin-associated kinase called link7 was
defined by Western blotting (Fig. 1C). The
lysates of Cos7 cells transfected with an
obscurin-associated MLCK-like kinase expres-
sion construct served as a positive control, and
the cells transfected with a non-coding, control
plasmid served as a negative control. To further
test the specificity of our antibody that we used
for the detection of obscurin-associated kinase,
we also expressed this protein in a mouse cell
line of fibroblast-like undifferentiated cells
transfected with a His-tagged full length
obscurin-associated kinase (its single kinase
isoform) and immunolabeled the cells with an
anti-His antibody. The results of these experi-
ments are presented in Figure 6A,B. We found
that the antibody intensely reacted to the
expressed protein localized in cell nuclei, and
no reaction was found in the samples treated
with the preimmune serum. This shows that the
antibody is specific for obscurin-associated
kinase.
Our experiments demonstrated that, unlike
obscurin, obscurin-associated kinase was local-
ized primarily to myonuclei, and that there was
intense expression of this protein in cardiac
myocytes with a poorly differentiated con-
tractile system (Fig. 7A–D). During myocyte
differentiation, we observed progressive redis-
tribution of obscurin-associated kinase to the
cytoplasm, particularly to the Z-bands of
myofibrils at advanced stages of differentiat-
ion (Fig. 8A–D). There was no immunore-
activity in non-myocyte nuclei (Figs. 7 and 8),
which clearly indicates that the expression
of obscurin-MLCK-like kinase is specifically
restricted to muscle cells. Taken together, these
data demonstrate that obscurin-associated
kinase is expressed early in cardiac muscle
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development and that its cellular localization is
differentiation-dependent.
The differential cellular localization of
obscurin and obscurin-associated kinase indi-
cates that these isotypes may have acquired
distinct but interrelated roles in vertebrate
muscle development during phylogenesis. The
close functional relationship of the two is
evident from the identification of a D. mela-
nogaster ortholog of obscurin that includes the
RhoGEF and multiple Ig domains characteristic
of the large obscurin and the kinase domains of
obscurin-associated kinase [Sutter et al., 2004].
Obscurin is also expressed in zebrafish muscle
[Raeker et al., 2006] where it appears to have
similar functions to the orthologs typical of
mammalian cardiac myocytes [Borisov et al.,
2004, 2006] and skeletal muscle cells [Kontro-
gianni-Konstantopoulos et al., 2006].
The coordinated temporal expression of
obscurin and its derivative obscurin-associated
kinase isoform and their possible evolution from
a single ancestral gene suggests the possibility
of their important functional relationships. The
cooperative activity of the kinase-like domains
and RhoGTPase signaling to the cytoskeleton
has been documented in recent years in other
proteins [O’Brien et al., 2000; reviewed by
Pfitzer, 2001]. It was shown that activation of
the RhoA pathway can inhibit myosin phospha-
tase activity, thereby enhancing the effects of
the kinase-mediated phosphorylation of myosin
light chain. There can also be inhibitory inter-
actions between the two signaling pathways
since PAK phosphorylation of MLCK by p21-
activated kinase, a kinase activated by the Rho
family of GTPases, can inhibit MLCK activity
[Hoshijima et al., 1998; Sanders et al., 1999;
Goeckeler et al., 2000].
Fig. 4. Cellular localization of obscurin in differentiating rat
cardiac muscle cells. A: Localization of obscurin in a poorly
differentiated rat early neonatal cardiac myocyte after 4 days in
culture; (B) localization of sarcomeric a-actinin in the same field;
(C) a merged image showing the localization of obscurin (red
fluorescence) anda-actinin (green fluorescence) in the same cell.
D: Structural interrelations of obscurin and sarcomeric a-actinin
localization in the area marked with the arrowhead in C shown at
a higher magnification. Note the topographical association of
intense immunolabeling for obscurin with the nascent myofi-
brillar system and its localization predominantly in the middle of
the A-band at the time of formation of mature myofibrillar
clusters. Also note that most of premyofibrillar structures
immunopositive for sarcomeric a-actinin are only weakly
immunopositive for obscurin. Bar, 20 mm (A–C), 6.4 mm (D).
[Color figure can be viewed in the online issue, which is available
at www.interscience.wiley.com.]
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Thus, the co-expression of obscurin and
obscurin-associated kinase suggests that there
may be an important regulatory interaction
between the kinase domains associated with
obscurin and the RhoGEF domain of this
protein. Whether this potential regulatory
relationship is active when two are physically
separate as occurs in the immature myocyte, or
is only present when the two co-localize at the
Z-bands of mature myofibrils remains to be
determined. However, despite the elements of
structural similarity of obscurin-associated
kinase to MLCKs, the functional role, the
catalytic properties and the substrates of this
enzyme-like protein remain to be elucidated.
Interestingly, a recent study by Bowman
et al. [2007] suggests that in adult rat skeletal
muscle fibers the localization pattern of two
alternatively spliced RhoGEF-containing ‘‘giant’’
obscurin isoforms is also differential. These
authors reported the development of an anti-
body to the RhoGEF domain of obscurin that
may serve as an important marker for the
studies focused on the structural and functional
interrelations of RhoGEF and the kinase-
regulated signaling pathways.
Obscurin was earlier found in the nascent
sarcomeres in the developing chicken and rat
myocardium in close association with titin
[Young et al., 2001]. At early stages of myofibril
formation, obscurin localizes to the Z-disk
where it appears to interact with the NH2-
terminal Z-disk region of titin and later incor-
porates into the middle of A-bands [Bang
et al., 2001; Young et al., 2001]. These data are
consistent with the results of the present study
of obscurin expression in developing myocar-
dium in situ and in cardiac muscle cells isolated
into differentiating cell culture. This interpre-
tation agrees with our conclusion concerning
Fig. 5. Localization of obscurin in cardiac myocytes during
mitosis. Double immunofluorescent labeling for obscurin (red
fluorescence) and sarcomeric a-actinin (green fluorescence) in a
rat neonatal cardiac muscle cell at the stage of early telophase of
mitosis. Two daughter nuclei (arrows) are visible in the central
area of the cytoplasm. Staining for nuclear DNA with Hoechst
dye (blue fluorescence) shows that the nuclei contain highly
condensed chromatin typical of the telophase of mitosis. Note
that obscurin is segregated in diffusely located granulated bodies
that are separated from the protein aggregates containing
sarcomerica-actinin. The fragmented remnants of the contractile
system disassembled during mitosis are seen at the cell periphery.
Bar, 10 mm. [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
Fig. 6. Immunofluorescent labeling for obscurin-associated protein kinase in the permanent line of H9c2
cells transfected with a non-coding control construct (A) and transfected with His-tagged construct encoding
obscurin-associated kinase (B). Note intense fluorescent labeling of anti-His n the nucleus of a transfected
cell in the center of the field in panel B. Arrowheads in B show the location of weakly and moderately
positive nuclei. Bar, 30 mm. [Color figure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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considerable upregulation of obscurin expres-
sion during cardiac development.
As we briefly mentioned above, the hallmark
structural motifs of the family of large muscle
proteins are the immunoglobulin (Ig), fibronec-
tin 3 (FN3), and serine/threonine kinase
MLCK-like domains. Multiple Ig and FN3
domains interact with other proteins anchoring
the kinase to specific intracellular sites and may
enable the interactions with specific target
molecules. They can also provide a physical
separation between functional domains of the
protein, allowing spatially distinct structural
and signaling interactions that are necessary
for highly ordered assembly of individual
elements of the contractile apparatus in cardiac
muscle.
Thus, the potential importance of obscurin,
and its associated proteins to striated muscle
development and physiology is indicated by
their patterns of expression during develop-
ment and their cellular localization in differ-
entiating cardiac myocytes. The fact that the
temporal pattern of their expression coincides
with the onset and activation of synthesis and
assembly of contractile sarcomeric proteins
in developing cardiac and skeletal muscle of
vertebrate embryos supports this assertion [for
literature on the time course of muscle develop-
ment see Lyons et al., 1990; Noden et al.,
1999; Buckingham et al., 2003]. Taken together,
these results suggest that the proteins encoded
by the obscurin transcriptional units are
directly involved in the progression of myogenic
differentiation. The upregulation of both of
obscurin and its associated kinase during
muscle development suggests that they may
have important cooperative roles in cardiac
myocyte differentiation. Correct sarcomere
assembly in new forming myofibrils depends
Fig. 7. Muscle-specific expression of obscurin-associated
kinase in cell cultures of differentiating rat neonatal cardiac
muscle cells as demonstrated by double immunolabeling for
the sarcomeric isoform of a-actinin (green fluorescence) and
obscurin-associated kinase (red fluorescence) on day 4 in
culture. A: Immunofluorescent labeling for sarcomeric a-actinin;
(B) immunofluorescent labeling for obscurin-associated kinase;
the insert shows the intense reactivity of cell nuclei and moderate
reactivity of the cytoplasm in the myocardial tissue section of
16-day old rat embryo (C) nuclear staining with Hoechst;
(D) combined image of A–C. Note the presence of immunor-
eactivity for obscurin-associated kinase only in a sarcomeric
a-actinin positive muscle cell (the arrowhead in B,C) and the
absence of obscurin-associated kinase expression in fibroblasts
whose nuclei are seen on the right side of the photo. Bar, 30 mm.
[Color figure can be viewed in the online issue, which is available
at www.interscience.wiley.com.]
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not only on the integrity of components of
the thick and thin filaments but also on the
intermediate filament and subsarcolemmal
proteins that link sarcomeres to the cytoskeletal
apparatus and mediate their interaction with
other cytoplasmic organelles. Loss-of-function
mutations in many of these cytoskeletal-
anchoring proteins can lead to sarcomere dis-
array, cardiac dilatation and congestive heart
failure. Further definition of the functional role
of these proteins during myogenesis and char-
acterization of their structural and regulatory
interrelations during myogenic differentiation
will be the focus of our future studies.
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